When it comes to medicus pharma to participate in the 38th annual roth conference, medicus Pharma Ltd., a leading biotech firm dedicated to advancing clinical development programs, has announced its participation in the 38th Annual Roth Conference scheduled for March 22-24, 2026, in Dana Point, California. The company is poised to highlight its innovative therapeutic asset, Skinject, particularly its potential efficacy in treating Gorlin Syndrome, an autosomal dominant rare disease. Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, will engage in a fireside chat to discuss the company's AI-enabled drug development strategies and readiness for partnerships with established pharmaceutical companies.
This year's Roth Conference will take place at The Ritz-Carlton Laguna Niguel, with Dr. Bokhari scheduled to present on March 24, 2026, from 12:30 PM to 12:55 PM Pacific Time. The conversation will be moderated by Jonathan Aschoff, Managing Director and Senior Research Analyst at Roth Capital Partners. A webcast of the fireside chat will be made available on demand to registered attendees, allowing wider access to Medicus Pharma's insights and future directions. Learn more on Investopedia.
Understanding Medicus Pharma To Participate In The 38th Annual Roth Conference
During the fireside chat, Dr. Bokhari is expected to delve into Skinject™, a localized immuno-oncology precision product designed to target non-melanoma skin diseases, particularly basal cell carcinoma (BCC) and Gorlin Syndrome. Gorlin Syndrome, also known as nevoid BCC syndrome, is a rare autosomal dominant disease affecting approximately 1 in 50,000 individuals. Medicus estimates that the combined market for BCC and Gorlin Syndrome treatment represents a significant opportunity of around $2 billion.
Skinject's innovative approach aims to provide a more effective treatment option for patients burdened by these conditions. The product leverages cutting-edge immunotherapy techniques, potentially transforming how these diseases are managed. Throughout the conference, Medicus Pharma executives will be available for one-on-one meetings with institutional investors and potential partners, emphasizing the company's commitment to collaborating with industry leaders to advance its therapeutic offerings.
AI-Enabled Drug Development Strategy
In addition to Skinject, Dr. Bokhari will outline Medicus Pharma's AI-enabled drug development strategy, which aims to streamline the discovery and optimization of new therapeutic candidates. By harnessing artificial intelligence, the company is enhancing its ability to identify promising drug candidates and reduce the time required for clinical development. This strategy aligns with industry trends toward more efficient, data-driven approaches in drug discovery.
Medicus's focus on advanced AI methodologies not only supports its internal pipeline but also positions the company as an attractive partner for other pharmaceutical firms seeking to leverage these innovative technologies. The ongoing integration of AI into Medicus Pharma's operations exemplifies its commitment to remaining at the forefront of biotech advancements, ultimately benefiting patients with unmet medical needs.
Strategic Partnerships and Future Directions
Medicus Pharma's strategic focus includes de-risking its key programs through Phase 2 proof-of-concept studies, followed by seeking licensing or partnerships for late-stage development and Commercialization. The company's approach is to compile robust clinical and regulatory data packages that support this partnership-oriented strategy, ensuring that prospective collaborators have the necessary information to make informed decisions.
Another key program that Dr. Bokhari plans to discuss is Teverelix®, an innovative GnRH antagonist designed for high-risk advanced prostate cancer patients and those experiencing acute urinary retention (AURr) episodes due to prostate enlargement. This product represents a market opportunity of approximately $6 billion, further demonstrating Medicus's diverse and compelling pipeline.
As the 38th Annual Roth Conference approaches, Medicus Pharma is keen to showcase its advancements in drug development and therapeutic innovation. The company's participation signals its commitment to transparency and collaboration within the biotech community. With groundbreaking products like Skinject and Teverelix, Medicus is well-positioned to make a significant impact in the treatment landscape for rare and prevalent diseases alike.
Originally reported by Globe Newswire. View original.